As market factors drive the rapid growth of decentralized clinical trials, organizations should embrace risk-based quality management to evaluate the new dimensions of risk and ensure effective oversight of disparate data sources, writes John Hall.
John Hall
Advertisement
SVP, EMEA & APAC, CluePoints
Articles by John Hall
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
Honing the Power of AI for Next Generation Trial Oversight and Execution
4
Driving Collaboration Across Functions to Streamline Drug Development
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
